Hypo, Hyper, or Combo: new paradigm for treatment of acute myeloid leukemia in older people

Acute myeloid leukemia (AML)[1][1] is a serious disease. Using the combination of cytarabine and daunorubicin developed during the 1970s,[2][2] with or without subsequent allogeneic stem cell transplantation (alloSCT),[3][3] we now cure more than half of all patients with de novo AML up to the age